(E)-2-(benzo[d]thiazol-2-yl)-3-(3,4-dimethoxyphenyl)acrylonitrile

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-2-(benzo[d]thiazol-2-yl)-3-(3,4-dimethoxyphenyl)acrylonitrile
• 英文别名: (E)-2-benzothiazol-2-yl-3-(3,4-dimethoxy-phenyl)-acrylonitrile；(2E)-2-(1,3-benzothiazol-2-yl)-3-(3,4-dimethoxyphenyl)prop-2-enenitrile；(E)-2-(1,3-benzothiazol-2-yl)-3-(3,4-dimethoxyphenyl)prop-2-enenitrile
• 化学式: C₁₈H₁₄N₂O₂S
• 分子量: 322.387
• InChiKey: NXZFFFBXXILHEW-UKTHLTGXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  83.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-氨基苯硫醇 在 哌啶 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 2.0h， 生成 (E)-2-(benzo[d]thiazol-2-yl)-3-(3,4-dimethoxyphenyl)acrylonitrile
  参考文献：
  名称：

  Mycobacterium tuberculosis lysine-ɛ-aminotransferase a potential target in dormancy: Benzothiazole based inhibitors

  摘要：

  MTB lysine-epsilon-aminotransferase (LAT) was found to play a crucial role in persistence and antibiotic tolerance. LAT serves as a potential target in the management of latent tuberculosis. In present work we attempted to derivatize the benzothiazole lead identified through high throughput virtual screening of Birla Institute of Technology and Science in house database. For Structure activity relationship purpose 22 derivatives were synthesized and characterized. Among synthesized compounds, eight compounds were found to be more efficacious in terms of LAT inhibition when compared to lead compound (IC50 10.38 +/- 1.21 mu M). Compound 22 exhibits bactericidal action against nutrient starved Mycobacterium tuberculosis (MTB). It also exhibits significant activity in nutrient starvation model (2.9 log folds) and biofilm model (2.3 log folds). 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2017.03.053

文献信息

• BCRP/ABCG2 INHIBITOR
  申请人：Yamazaki Ryuta

  公开号：US20090253656A1

  公开（公告）日：2009-10-08

  The present invention is directed to a breast cancer resistance protein (BCRP/ABCG2) inhibitor. The BCRP inhibitor contains, as an active ingredient, an acrylonitrile derivative represented by formula (1): wherein one of R 1 and R 2 represents a cyano group and the other represents a hydrogen atom; Ar 1 represents a group selected from among the groups represented by formulas (2) to (4): and Ar 2 represents an aromatic hydrocarbon group having a condensed ring which may be substituted by a halogen atom, or a group selected from among the groups represented by the following formulas (5) to (15): or a salt thereof.

  该发明涉及一种乳腺癌耐药蛋白（BCRP/ABCG2）抑制剂。该BCRP抑制剂包含以下化合物作为活性成分，其化学式为（1）：其中R1和R2中的一个代表氰基，另一个代表氢原子；Ar1代表从以下化学式（2）至（4）中选出的一种基团：Ar2代表一种含有可能被卤素原子取代的融合环的芳香烃基团，或者从以下化学式（5）至（15）中选出的一种基团：或其盐。
• BCRP/ABCG2 inhibitor
  申请人：Yamazaki Ryuta

  公开号：US08697742B2

  公开（公告）日：2014-04-15

  A breast cancer resistance protein (BCRP/ABCG2) inhibitor. The BCRP inhibitor contains, as an active ingredient, an acrylonitrile derivative or a salt thereof.

  一种乳腺癌抗性蛋白（BCRP/ABCG2）抑制剂。该BCRP抑制剂含有丙烯腈衍生物或其盐作为活性成分。
• BCRP/ABCG3 Inhibitor
  申请人：Kabushiki Kaisha Yakult Honsha

  公开号：EP2332905A1

  公开（公告）日：2011-06-15

  A BCRP inhibitor comprising, as an active ingredient, an acrylonitrile derivative represented by formula (1): wherein one of R1 and R2 represents a cyano group and the other represents a hydrogen atom; Ar1 represents a group selected from among the groups represented by formulas (2) to (4): wherein R7 and R8, which are identical to or different from each other, each represent a hydrogen atom, a halogen atom, or a lower alkoxy group; A represents an oxygen atom, a sulfur atom, or NR9; and R9 represents a hydrogen atom or a lower alkyl group; Ar2 represents a group selected from among the groups represented by formulas (5) to (15): wherein R3 represents a hydrogen atom, an oxygen atom (as N-oxide), a lower alkyl group, a lower alkoxy group, a halogen atom, a nitro group, a methylsulfanyl group, a lower hydroxyalkyl group, an aromatic hydrocarbon group which may have a substituent, or NR5 (R6) R5 and R6, which are identical to or different from each other, each represent a hydrogen atom, a lower alkyl group which may have a substituent, a lower hydroxyalkyl group, or an aromatic hydrocarbon group which may have a substituent or heterocyclic group; R5 and R6 may form, with their adjacent nitrogen atom, a heterocyclic ring which may have a substituent; and the hydroxyl group of the lower hydroxyalkyl group or the heterocyclic ring substituted by a hydroxyl group or a lower hydroxyalkyl group may form an ester bond with a phosphoric acid group or a salt thereof or with an acyl group which may have a substituent; R4 represents a hydrogen atom, a lower alkyl group, a phenyl group which may have a substituent, or a benzyl group; X represents a carbon atom, CH, or a nitrogen atom, provided that when A is an oxygen atom, X is not a nitrogen atom; and A, R7, R8, and R9 have the same meanings as defined above; or a salt thereof.

  一种 BCRP 抑制剂，其活性成分包括由式（1）表示的丙烯腈衍生物： 其中 R1 和 R2 中的一个代表氰基，另一个代表氢原子； Ar1 代表选自式（2）至（4）所代表基团中的一个基团： 其中彼此相同或不同的 R7 和 R8 各自代表氢原子、卤素原子或低级烷氧基； A 代表氧原子、硫原子或 NR9；以及 R9 代表氢原子或低级烷基； Ar2 代表选自式 (5) 至 (15) 所代表基团中的一个基团： 其中 R3 代表氢原子、氧原子（作为 N-氧化物）、低级烷基、低级烷氧基、卤素原子、硝基、甲硫 基、低级羟烷基、可具有取代基的芳香烃基或 NR5 (R6) 彼此相同或不同的 R5 和 R6 分别代表一个氢原子、一个可带取代基的低级烷基、一个低级羟烷基或一个可带取代基或杂环基的芳香烃基；R5 和 R6 可与相邻的氮原子形成一个可带取代基的杂环；下羟烷基的羟基或被羟基或下羟烷基取代的杂环可与磷酸基团或其盐或可带有取代基的酰基形成酯键； R4 代表氢原子、低级烷基、可能具有取代基的苯基或苄基； X 代表碳原子、CH 或氮原子，但当 A 是氧原子时，X 不是氮原子；以及 A、R7、R8 和 R9 具有与上述定义相同的含义；或其盐。
• BCRP/ABCG2 Inhibitor
  申请人：Kabushiki Kaisha Yakult Honsha

  公开号：EP2332905B1

  公开（公告）日：2017-03-01
• US8697742B2
  申请人：——

  公开号：US8697742B2

  公开（公告）日：2014-04-15